Back to top
more

Black Diamond Therapeutics (BDTX)

(Delayed Data from NSDQ)

$5.89 USD

5.89
566,898

+0.78 (15.26%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.77 -0.12 (-2.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%

by Zacks Equity Research

The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)

by Zacks Equity Research

Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

What's in the Cards for Doximity (DOCS) in Q2 Earnings?

by Zacks Equity Research

Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

by Zacks Equity Research

Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.

Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season?

by Zacks Equity Research

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Coupa Software's (COUP) BSM Platform Adopted by World Vision

by Zacks Equity Research

Coupa Software (COUP) is likely to benefit from coronavirus-induced robust demand for the company's BSM offering.

Coupa Software (COUP) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Coupa Software's (COUP) first-quarter fiscal 2021 results benefit from coronavirus crisis-triggered robust demand for Coupa BSM and market traction of Coupa Pay offerings.

How Black Diamond Therapeutics (BDTX) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex

by Zacks Equity Research

Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Disappointing Data

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Black Diamond Therapeutics, Inc. (BDTX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 27th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: